- Blog
- News & Media
- Issues
- About The Biopharmaceutical Sector
- Access and Affordability
- Adherence
- Appropriate Use Of Medicines
- Counterfeit Drugs
- Disaster Response
- Drug Safety
- Environmental Issues
- Food And Drug Administration
- Importation
- Intellectual Property
- International
- Medical Advances
- Medicare
- Prescription Drug Abuse
- Prescription Drug User Fee Act
- Sales And Marketing
- Research
- About
Profiles and Reports
Growth Platform For Economies Around the World
A new study by the Battelle Technology Partnership Practice examines the increasing efforts by other countries to grow their economies by focusing on the biopharmaceutical sector and related industries.
On the Catalyst: The U.S. currently leads the world in medical innovation. But for how long?
Chart Pack
Our Chart Pack, “Biopharmaceuticals in Perspective,” contains useful facts and figures about prescription medicines and their role in the health care system, as well as in America's overall economy. Bookmark it today.
Industry Profile 2012
The annual 2012 Pharmaceutical Industry Profile provides an overview of the sector, highlighting the latest medical advances, the impact of biopharmaceutical companies on the economy and the future of innovation.
Read the 2012 Industry Profile.
Experience the 2012 Pharmaceutical Industry Profile in a new interactive format on your iPad. Stay tuned for the iBooks version which will be made available here shortly and in the iTunes Bookstore.
Battelle Report on Economic Impact
The U.S. biopharmaceutical industry develops medicines that save, sustain and improve lives. The industry is also well recognized as a dynamic and innovative business sector generating high-quality jobs and powering economic output and exports for the U.S. economy. This report quantifies this economic impact of the biopharmaceutical sector on the U.S. economy and jobs. Using input/output analysis, this report measures the direct and indirect impacts of the biopharmaceutical sector, and quantifies the economic impacts that would occur if biopharmaceutical revenues increase or decrease from significant changes in the business operating environment.
Driving State Economic Growth in the 21st Century: Advancing the Biopharmaceutical Sector
The biopharmaceutical industry contributes significantly to national, state, and local economies. Recognizing this sector’s contributions to state economies in terms of providing high‐value, high‐wage, revenue‐generating jobs, PhRMA commissioned Battelle to conduct this study to examine the extent to which state governments are targeting the industry for economic growth and development.
Read state specific fact sheets.
Archstone Report on Economic Impact
Despite the economic challenges of recent years, America's biopharmaceutical research companies remain a major source of employment throughout the United States. The sector also contributes to the nation's economy in various ways, including contribution to GDP, taxes, R&D spending, intellectual property, and exports.
Discoverers Award 2011: JANUVIA®
Two Merck research scientists, Nancy A. Thornberry and Ann E. Weber, Ph.D., received the 2011 Discoverers Award, the highest honor from PhRMA. They were recognized for their leadership in the discovery of JANUVIA®, a once-daily pill that helps patients with type 2 diabetes control glucose in conjunction with diet and exercise.
Pharmaceutical Marketing & Promotion
Activities conducted as part of pharmaceutical marketing and promotion are an important part of informing consumers and healthcare professionals about new treatments. This booklet offers facts that we believe are important to consider as the value of marketing and promotion is debated.
Learn more about marketing & promotion.
Drug Discovery and Development
For the first time in history, scientists are beginning to understand the inner workings of human disease at the molecular level. Recent advances in genomics, proteomics and computational power present new ways to understand illness. The task of discovering and developing safe and effective drugs is even more promising as our knowledge of disease increases.
Annual Report 2011
PhRMA’s mission is winning advocacy for public policies that encourage the discovery of life-saving and life-enhancing new medicines for patients by pharmaceutical/biotechnology research companies. To accomplish this mission, PhRMA is dedicated to achieving in Washington, D.C., the states and the world:
Broad patient access to safe and effective medicines through a free market, without price controls;
Strong intellectual property incentives, and;
Transparent, efficient regulation and a free flow of information to patients.
Read more about our mission in the 2011 annual report.
Corporate Philanthropy in Asia
A dozen nations and as many companies are represented in this, the first report by the Pharmaceutical Research and Manufacturers of America of philanthropic activities of the world’s leading research-based pharmaceutical companies in Asia. The myriad philanthropic activities found in Corporate Philanthropy in Asia include well over 300 separate initiatives of a wide range of sizes, shapes and purposes.
Decade of Innovation: Advances in the Treatment of Rare Diseases
In the last 10 years, biopharmaceutical companies have made great progress in the fight against rare diseases. Over 160 drugs were approved during the past decade (1995–2005) to treat rare or “orphan” diseases that affect 200,000 or fewer people in the United States. This compares with 108 approvals in the decade before (1984–1994) and fewer than 10 in the 1970s. Each of these medicines offers hope and relief to patients with diseases that often have no other treatment options.
Health Care in the Developing World
An unknown fact about the industry is the important role they play in the global effort to fight disease and improve public health in the developing world. In both absolute and relative terms the industry’s global humanitarian programs are substantial, sustained and effective. In a span of three years the industry’s global healthcare spending increased 148 percent, from $564 million to $1.4 billion. Another study puts the industry’s contribution at $2.1 billion. Our contribution to global health represents more than a third of the United States’ total healthcare assistance to the developing world.
The Value of Investment in Health Care Executive Summary
Over the past few decades, significant advances in the U.S. health care system have helped people live longer and better lives. In fact, both mortality and disability rates have fallen consistently since the 1970s. This period has also seen substantial increases in health spending. All too often, health care discussions seem to center on the substantial increase in per person spending on health care during this period, rather than the benefits of improved health care that the spending brought.
A Decade of Innovation: Advances in the Pharmaceutical Treatment of Disease
Over the past decade, pharmaceutical companies have pushed the scientific envelope, working at the cellular and molecular levels to dramatically advance the treatment of disease. At the end of 2002, 28 percent more medicines were being investigated by pharmaceutical companies for approval by the Food and Drug Administration (FDA) than was true one decade before. More than 1,000 medicines are now in the development pipeline.
